Aurinia Pharmaceuticals Inc. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, dated May 14, 2019, reports on the interim period ended March 31, 2019. The filing incorporates by reference the Interim Condensed Consolidated Financial Statements and Management's Discussion and Analysis (MD&A) for the first quarter of 2019. The registrant is a foreign private issuer filing under Form 40-F.
Key Financial Metrics
The provided text serves as a cover sheet and exhibit index. It does not contain the actual financial data. Specific values for revenue, profit, cash flow, margins, debt, and liquidity are not present in this excerpt; they are located in the incorporated Exhibits 99.1 and 99.2.
Material Changes
No material changes or comparative period data are disclosed in the provided text. The filing text does not provide a clear value for any financial metric changes.
Guidance, Outlook, and Risks
The text does not include management commentary, guidance, outlook, risks, contingencies, or unusual items. These details are contained within the MD&A (Exhibit 99.2) referenced in the filing but not included in the input text.
Investor Verification Checklist
- Review Exhibit 99.1 for the specific Q1 2019 revenue, net loss, and cash position.
- Examine Exhibit 99.2 for the MD&A to understand the burn rate and runway.
- Verify the status of the Form F-10 Registration Statement (File No. 333-222413) referenced in the filing.
- Confirm the certifications provided by the CEO and CFO in Exhibits 99.3 and 99.4.